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Abstract
Background: Repeated mass azithromycin distributions are effective in controlling the ocular strains of chlamydia that
cause trachoma. However, it is unclear when treatments can be discontinued. Investigators have proposed graduating
communities when the prevalence of infection identified in children decreases below a threshold. While this can be tested
empirically, results will not be available for years. Here we use a mathematical model to predict results with different
graduation strategies in three African countries.
Methods: A stochastic model of trachoma transmission was constructed, using the parameters with the maximum
likelihood of obtaining results observed from studies in Tanzania (with 16% infection in children pre-treatment), The Gambia
(9%), and Ethiopia (64%). The expected prevalence of infection at 3 years was obtained, given different thresholds for
graduation and varying the characteristics of the diagnostic test.
Results: The model projects that three annual treatments at 80% coverage would reduce the mean prevalence of infection
to 0.03% in Tanzanian, 2.4% in Gambian, and 12.9% in the Ethiopian communities. If communities graduate when the
prevalence of infection falls below 5%, then the mean prevalence at 3 years with the new strategy would be 0.3%, 3.9%, and
14.4%, respectively. Graduations reduced antibiotic usage by 63% in Tanzania, 56% in The Gambia, and 11% in Ethiopia.
Conclusion: Models suggest that graduating communities from a program when the infection is reduced to 5% is a
reasonable strategy and could reduce the amount of antibiotic distributed in some areas by more than 2-fold.
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Introduction
Over 40 million doses of oral azithromycin have already been
distributed to control the ocular strains of chlamydia that cause
trachoma [1]. The World Health Organization (WHO) advocates
three annual community-wide distributions and continued treat-
ment until clinical evidence of infection falls below a threshold
where resulting blindness should not be a major public health care
concern. These distributions have proven effective in reducing
infection in longitudinal studies, individual-randomized trials, and
community-randomized trials [2–14]. Studies have also suggested
that in some circumstances distributions may be safely discontin-
ued, either because infection has been eliminated, or the few
remaining infections may disappear on their own [7,8,10,12–14].
Laboratory testing offers the possibility of graduating communities
that no longer need to receive mass antibiotics, reducing expense,
side-effects, and the potential for developing drug resistance in
other organisms such as Streptococcus pneumonia [13,15]. Here we
explore the effect of graduating communities from a treatment
program, with graduation being defined as a point in time when a
community will no longer receive mass antibiotic distributions
because evidence of infection is below a prescribed threshold.
Less expensive diagnostic laboratory testing for infection may
become available for trachoma programs in the near future.
Estimates of the prevalence of infection using PCR-based tests can
be made more cost-effective by sampling individuals within
communities and by pooling several samples into one test
[6,10,14,16,17]. There is hope that a low cost, point-of-care
(POC) test will become available which will allow on-the-spot
identification of infected communities [18]. Strategies to graduate
communities when the prevalence of infection has decreased
below a threshold are now being tested. However, the results will
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not be available for years, and only one strategy can be tested at a
time. Here we use data from three African countries to fit a
stochastic mathematical model, and then predict the results of two
different treatment programs, three annual mass treatments
consistent with WHO recommendations versus three annual mass
treatments using strategies to graduate communities.
Methods
Clinical data
Data were collected in three countries at baseline, and 2 and 6
months after treatment as previously described [6,8,19].
Informed consent along with institutional review board approval
was given in each of the studies as described [6,8,19]. Although
there were differences in the underlying study designs in the three
countries, the similarities allow comparable data sets to be
abstracted from each. In all three sites, there was a baseline mass
oral azithromycin distribution, and then no subsequent azithro-
mycin treatment until after the 6 month collection. In all three
sites, all individuals aged one year and older were offered a single
dose of oral azithromycin during mass treatments. Pregnant
women and those allergic to macrolides were offered alternative
treatment (topical tetracycline). The right upper conjunctiva of
each child was swabbed, and the swab was then tested for the
presence of chlamydial DNA using Amplicor PCR (Roche
Diagnostics, Branchburg, NJ). In Ethiopia, sixteen villages in
the Gurage region of southern Ethiopia were randomly selected
and 1–5 year old children, the ages most likely to harbor
infection, were monitored [6]. In Tanzania and in The Gambia,
swabs were taken from all individuals of all ages, although for the
purposes of this study, we use only swabs taken from children
aged 1–10 years. In Tanzania and The Gambia, 15 balozis (a
household administrative unit consisting of about 10 households),
and 14 villages, respectively, were followed [7,8].
Mathematical models
Previously, we constructed a simple stochastic SIS model
(Susceptible, Infected, Susceptible) of ocular chlamydial infection
in a core group of children [20,21]. In this report, the previous
model was modified to include infection from outside of the
community, and a transmission term that can vary between
communities in the same region as a normally distributed random
effect (to account for the known variability of communities).
Treatment strategies that allowed graduation of communities
when observed infection fell below a certain threshold, as detected
by a POC test, were incorporated. Specifically, we constructed a
Markov model by letting pi tð Þ denote the probability that there are
i infected individuals in the population at time t (where i varies
from 0 to N). At scheduled treatments, we assumed that each
infected individual had an 80% chance of being treated (the
WHO-recommended coverage rate), and if treated would revert to
being susceptible. Between periodic mass treatments, the model is
a standard continuous time Markov process. We assumed
equilibrium at baseline, that infected individuals recover naturally
at rate c, that uninfected individuals become infected at rate b I/N
from sources within the community (with b=R0?c), and at a rate
of n from outside the community (with n decreasing to zero once
Author Summary
Trachoma, the major cause of infectious blindness in the
world, occurs when repeated infections of the ocular
strains of Chlamydia trachomatis lead to a cascade of
conjunctival scarring, in-turned eyelids and eyelashes, and
eventually blindness due to corneal opacity. To reduce the
prevalence of infection, the World Health Organization
(WHO) advocates at least three annual community-wide
distributions of oral antibiotics in affected areas. This
approach has proven effective, but there is room to
explore other treatment strategies which reduce the use of
antibiotics. Here, we used mathematical models and data
from three trachoma-endemic countries (Tanzania, The
Gambia, and Ethiopia) to analyze different treatment
strategies. In the simulations, we show that a graduation
strategy can reduce antibiotic distributions more than 2-
fold in moderately affected areas. Both treatment strate-
gies provide favorable results in reducing the prevalence
of ocular chlamydia, but high costs and the potential for
resistance are important issues to consider when admin-
istering mass doses of antibiotics.
Table 2. Estimated model parameters for each of the three data sets.
Country R0 (95% CI)
Standard Deviation of R0
(95% CI)
Recovery Rate, Gamma (95%
CI) weeks21
Exogenous infection rate,
Nu (95% CI) weeks21
Tanzania 0.89 (0.50, 1.27) 0.001 (0.000, 0.576) 0.037 (0.001, 0.073) 0.002 (0.000, 0.004)
The Gambia 1.01 (0.66, 1.36) 0.724 (0.001, 1.447) 0.052 (0.000, 0.113) 0.0002 (0.000, 0.001)
Ethiopia 3.14 (2.51, 3.77) 0.7315 (0.232, 1.231) 0.0123 (0.005, 0.02) 0.001 (0.000, 0.002)
doi:10.1371/journal.pntd.0000458.t002
Table 1. Characteristics of three data sets.
Country Mean Baseline Prevalence (95% CI)
Mean number of Children per
Village (Ages 0–9)
Total Number of
Communities References
Tanzania 16% (10%, 22%) 24 15 19
Gambia 10% (0%, 20%) 38 14 8
Ethiopia 64% (56%, 72%) 50 16 6
doi:10.1371/journal.pntd.0000458.t001
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Figure 1. Simulations assessing the effect of graduation on prevalence of infection. Each curve represents the mean of 1000 stochastic
simulations of community prevalence of ocular chlamydial infection in children with three annual mass treatments versus annual mass treatments
with graduation, in Tanzania (A), the Gambia (B), and Ethiopia (C). In the graduation strategy, communities received an initial mass treatment, and
two subsequent annual mass treatments until the prevalence was reduced below 5%.
doi:10.1371/journal.pntd.0000458.g001
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Figure 2. Simulations comparing the effect of graduation on eliminating infection in communities. Each curve represents the proportion
of 1000 simulated communities which still harbor infection, in Tanzania (A), the Gambia (B), and Ethiopia (C). Note that in Tanzanian and Gambian
simulations, some communities had no identifiable infection pre-treatment, which is consistent with the observed data).
doi:10.1371/journal.pntd.0000458.g002
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wide-spread programs have begun), leading to the following set of
N+1 Kolmogorov-forward equations:
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For clarity, we expressed b in terms of the basic reproductive
number, R0 (where b=R0?c). Note that R0 is defined as the mean
number of secondary infectious cases caused by a single infectious
case in an otherwise completely susceptible community [22]. At
the time of the scheduled periodic mass treatments, we assume
that each infected individual has a probability c of being treated
(the effective coverage), with the number of infections post
treatment being drawn from the corresponding binomial distri-
bution.
Parameters for this stochastic model were fitted to baseline and
6-month data for each country using maximum likelihood
estimation. We initiated simulations at the average prevalence
for that region, and simulated the Kolmogorov-forward equations
for 40 years to allow the distribution of prevalence to approximate
the pre-treatment distribution at time point zero. We also initiated
the model at the observed 2-month prevalence and simulated the
equations for 4 months to estimate the expected distribution of
prevalence at 6-months. The total log-likelihood was the sum of
the baseline and the 6 month log-likelihoods for each of the
communities in the area. Note that any event that occurred
between baseline and 2-months (such as treatment, or mass re-
infection from travel) would not bias these results [8]. Based on
these Kolmogorov equations, the values of the parameters R0,
standard deviation of R0 (thus treating R0 as a random effect), c,
and n that maximized the probability of obtaining the observed
baseline and 6-month data for that country (i.e. the likelihood)
were determined using an iterative, hill-climbing algorithm.
Figure 3. Sensitivity of simulated prevalence on the choice of parameter values. Here we in turn varied the threshold for graduation (A),
sensitivity of the diagnostic test (B), specificity of the diagnostic test (C), R0 (D), recovery rate c (E), and exogenous rate n (F). The mean prevalence at 3
years for 1000 simulations is displayed as the parameter is varied, for each of the three countries. Parameters which were not varied were assumed to
be as in Table 2.
doi:10.1371/journal.pntd.0000458.g003
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Numerical optimizations were repeated a minimum of 4 times
from random starting points (because of the possibility any single
run could converge to a local, rather than the global, maximum);
each iteration converged to the same value. Furthermore, a grid
search did not reveal any greater maxima.
The variance of these estimates was assessed by inverting the
Hessian of the log-likelihood evaluated at the maximum likelihood
estimate (although note that the 95% confidence interval could not
include n=0, because in each country, a community went from 0
infections at 2 months to.0 infections at 6 months). Coverage was
assumed to be 80%, and the average population size was set at the
mean of empirical results from the surveyed communities in that
region (Table 1). For sensitivity analyses, we ran 1000 simulations
with the fitted parameters under different scenarios. We varied the
sensitivity and specificity of the POC test, as well as the threshold
for declaring graduation, keeping R0, standard deviation of R0, c,
and n at the optima found for that region. If not being varied, the
sensitivity and specificity of a POC diagnostic test were set at 70%
and 99% respectively, and the prevalence threshold for graduating
communities of #5%. All analyses were carried out in Mathematica
5.2.
Results
Characteristics of the observed data from the three countries
are shown in Table 1. Tanzania had a higher mean prevalence
than The Gambia, but there was a larger variation in
prevalence in Gambian communities, with some having as high
as 40% and nearly two-thirds not having any infection
identified. Ethiopia had high prevalences in all communities.
These areas of Tanzania and The Gambia would be considered
meso-endemic or hypo-endemic areas, and the area of Ethiopia
hyper-endemic. Predicted model parameters are displayed in
Table 2. The mean basic reproduction number, R0, and the
estimate of the standard deviation of R0 (treating the particular
R0 in a community as a random effect), the recovery rate, c, and
the exogenous infection rate, n, are displayed for the data sets
from each country, along with the 95% confidence intervals for
these parameter estimates. The Ethiopian data resulted in the
highest estimated mean R0, while the largest coefficient of
variation for R0 was found in The Gambia, consistent with the
observed heterogeneity between villages found there. The
exogenous infection rate is dependent not only on the overall
Figure 4. Sensitivity of elimination of infection on the choice of parameter values. The proportion of communities which still harbor
infection at 36 months is displayed as the parameter is varied, for each of the three countries. Parameters varied are threshold for graduation (A),
sensitivity of the diagnostic test (B), specificity of the diagnostic test (C), R0 (D), recovery rate c (E), and exogenous rate n (F). Parameters which were
not varied were assumed to be as in Table 2.
doi:10.1371/journal.pntd.0000458.g004
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prevalence of infection in an area, but the proximity of the
defined communities in each country.
The WHO-recommended strategy of three annual mass
treatments (before subsequent re-evaluation for further treatment)
resulted in an estimated mean prevalence of 0.0% in Tanzanian,
2.4% in Gambian, and 12.9% in Ethiopian communities at three
years (Figure 1A, 1B, and 1C). In addition, results showed
complete elimination of infection in 99.8% of Tanzanian
communities, 93.3% of Gambian communities, and 39.8% of
Ethiopian communities (Figure 2A, 2B, and 2C).
With a strategy of graduating communities from further mass
antibiotics when the observed prevalence of infection falls below
5%, the estimated mean prevalence at 3 years was 0.3% in
Tanzania, 3.9% in The Gambia, and 14.4% in Ethiopia
(Figure 1A, 1B, and 1C). The proportion of communities where
elimination would be expected was 97.6% in Tanzania, 88.8%
in The Gambia, and 30.0% in Ethiopia (Figure 2A, 2B, and
2C). Elimination in each of the three countries is affected by the
threshold for graduation, sensitivity and specificity of the
diagnostic test, R0, recovery rate, and the exogenous rate
(Figures 3 and 4). Increasing the threshold for graduation
marginally increased the median prevalence of infection at 36
months (Figure 3) and the proportion of communities in which
infection could still be identified (Figure 4). As one might expect,
increasing either R0 or the exogenous rate increases prevalence
and decreases the proportion of villages which attain infection
elimination (Figures 3 and 4). However, these sensitivity
analyses suggest that the simulation results are not dependent
on the exact choice of the sensitivity and specificity of the
diagnostic test. Increasing the recovery rate (c) allows the
prevalence of infection to return to the equilibrium of the region
more rapidly.
Figure 5 shows the amount of antibiotics used during three years
of the graduation strategy, compared to three years of annual
treatment. The graduation strategy, over the three year period,
would reduce treatments by 63% in the Tanzanian communities,
56% in Gambian communities, and 11% in the Ethiopian
communities, compared to annual treatments. These reductions
in treatments are also affected by alterations in the threshold for
graduation, test sensitivity, and test specificity (Figure 6). Increas-
ing the specificity has a marked reduction in antibiotic use
(Figure 6C). Note that if the specificity falls low enough, then more
than 5% infections will be ‘‘observed’’ due to false positives. In this
case, there will be no graduations, regardless of the true prevalence
of infection.
Discussion
The WHO’s recommendation of a minimum of three annual
antibiotic distributions with at least 80% coverage should work
well in most areas. In the models representing Gambian and
Tanzanian communities, infection was eliminated in more than
95% of communities during the first three years of a WHO-
recommended treatment program, consistent with later observed
results in the Tanzanian communities [13]. Note that the WHO
recommends reassessment at this point, and further antibiotic
distributions if the clinical signs of infection are still present. Most
communities in these areas will have eliminated infection in
children after 3 annual treatments.
In hyper-endemic areas like the studied in Ethiopia, we expect 3
years of treatment to eliminate infection in 40% of communities.
This is consistent with a recent community-randomized clinical
trial in a nearby area of Ethiopia [14]. We have previously
suggested that biannual treatment in hyper-endemic areas may be
a more successful strategy to eliminate infection, at least in a 2–5
year time frame [14,23].
A strategy that graduates communities when the observed
prevalence of infection in children falls below 5% appears to be
reasonable. The models presented here predict that treatment
could be discontinued in the vast majority of communities similar
to those studied in Tanzania and The Gambia. Graduating
communities had only a minimal effect on the mean prevalence of
Figure 5. Treatment savings with graduation strategy. The percentage of individuals treated at each annual visit with mass treatment versus a
graduation strategy. Note that we assume an 80% coverage for mass antibiotic treatments.
doi:10.1371/journal.pntd.0000458.g005
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infection found in the area at the end of a 3-year trachoma
program. This is because trachoma transmission is low in many of
the Tanzanian and Gambian communities, and because the
graduation strategy favors re-treating the communities which have
higher transmission. We predict that antibiotic use could be
reduced 2 to 3-fold by introducing such measures, and even more
if the graduation threshold were applied before the first
treatment—here, we treated all communities at least once.
Figure 6. Sensitivity of treatment savings on parameter values. The percentage of treatments saved with a graduation strategy is displayed
as the threshold for graduation (A), sensitivity of diagnostic test (B), or specificity of diagnostic test (C) is varied. Parameters which were not varied
were assumed to be as in Table 2.
doi:10.1371/journal.pntd.0000458.g006
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The goal of trachoma programs is to efficiently use resources to
eliminate trachoma as a public health concern. The cost of
providing treatment for a community in Africa, estimated at
$0.25–1.00 per individual, includes the costs of antibiotics, as well
as wages for health workers and administrators [24]. These costs
can be expected to result in a 75–90% reduction in ocular
chlamydial prevalence at one year after treatment, per mass
distribution [7,9,10,14]. However, the cost-effectiveness of a
program is determined by more than treatment costs and
reduction of infection. Trachoma programs must decide which
communities to treat, and when to stop treatment. As shown in
this study, this decision will require knowledge of the prevalence of
chlamydial infection, since areas with highly prevalent chlamydial
infection will likely require longer periods of treatment. The costs
of diagnosing ocular chlamydial infection vary. Currently,
chlamydial infection is usually assessed with the clinical conjunc-
tival exam [25]. Although the clinical exam is relatively
inexpensive (costs include only the examiner’s time), it is not
particularly accurate in identifying chlamydial infection, particu-
larly after treatment [26]. Chlamydial PCR is an alternative,
though it is expensive when performed for an individual ($12–20
per test, personal communication, V. Cevallos, F.I. Proctor
Foundation). Because trachoma programs base treatment deci-
sions not on individuals, but on the entire community, samples
could be pooled for PCR testing, which would result in
considerable savings ($2–3 per individual tested, assuming 5
samples per pool) [16,17]. A point of care test for chlamydia may
also provide a less expensive method for diagnosing ocular
chlamydia ($0.70 per individual tested) [18]. Besides the inclusion
of these additional costs, there are additional outcomes that play a
role in the cost-effectiveness of trachoma control. Specifically,
while the outcomes of antibiotic treatment programs can easily be
measured as the reduction in ocular chlamydial infection, the true
outcome of interest is the reduction of blindness. However, the
progression from infection to blindness in individuals can take
decades, and rates are difficult to assess. Of note, treatment efforts
besides antibiotics, such as promotion of face-washing and
construction of latrines, may also be administered by trachoma
programs, though the effectiveness of these measures has not been
proven, making their role in cost-effectiveness difficult to study at
present.
Mathematical models of trachoma control can be useful in
determining optimal distribution strategies, and predicting what is
expected from specific programs. Stochastic models have an
advantage over deterministic models in this setting, because they
include the effect of chance seen with the low levels of infection in
communities near elimination. Models must also include variation
between regions, since strategies that have proven effective in
hypo-endemic areas may not translate to hyper-endemic areas.
Models should also include variation between communities in the
same region. To incorporate this community variation into a
realistic model, we included a community-level random effect in
transmission (specifically, variation in the underlying R0 for each
community). The results confirm that there is likely some
variability between neighboring communities even beyond that
which would be expected by chance. Incorporating further mixing
structure, for example preferential mixing within a household,
might create more variance between simulated communities,
reducing the need to introduce a random effect at the community-
level as we have done here. The graduation strategy appears to be
effective over a wide range of parameter choices in the Tanzanian
and the Gambian communities studied here. More endemic areas
such as those found in Ethiopia, appear more sensitive to
parameter choices, and are far more vulnerable to reinfection.
There is a long history of the use of mathematical models of the
transmission of infectious diseases. These are often used to make
theoretical points, which do not require precise parameter
estimates. Even when parameters are fitted to data, they are
rarely fitted to data from more than one community. Community
trials in trachoma control have provided longitudinal prevalence
data in 14–16 communities in each of three sub-Saharan African
countries. There are still many limitations of this simple model
which can be explored in the future. We have included only
transmission in children, the age group known to harbor most of
the infection, but adults could be included with available data. We
have assumed that individuals do not gain or lose immunity over
the 3 year program, and that there is no antibiotic resistance; the
importance of these factors has been debated [11,27,28]. Our
model defines the rate of contact to be independent of the
population size (since the mass action term is divided by the
effective population size N)—other assumptions such as density
dependent transmission are also possible. Finally, we have
assumed that treatment of children on a given visit is independent
of past treatment history. Were treatments to miss the same 20%
of children each time, then infection might linger longer in this
subgroup.
Repeated mass oral azithromycin distribution will be effective in
reducing the prevalence of ocular chlamydia. But distribution costs
are high, and side effects and the potential for resistance are
important issues. Graduating communities when diagnostic testing
reveals a prevalence of ocular chlamydia of 5% or less appears to
be an appropriate strategy in most areas. More frequent treatment
and different stopping rules may be required for more hyper-
endemic areas similar to the region of Ethiopia studied here.
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